Elahere

News

ESMO26: Lilly's sofe-m ADC stakes a claim in ovarian cancer

Eli Lilly's first major readout at ESMO comes from a phase 1 trial of its FRα-targeting sofe-m in platinum-sensitive ovarian cancer (PSOC).

News

AbbVie's ovarian cancer drug Elahere gets NHS green light

AbbVie's Elahere has become the first new NHS therapy in more than 20 years for resistant ovarian cancer, providing an alternative to chemotherapy.

News

Data backs GSK's ovarian cancer blockbuster hopes

GSK's B7-H4-targeting ADC Mo-Rez chalks up impressive results in ovarian and endometrial cancer, prompting a major phase 3 trials programme.

News

AbbVie builds the case for ovarian cancer drug Elahere

AbbVie hopes for another lift to its fast-growing ovarian cancer drug Elahere with new survival data.

News

AbbVie bags EU nod for key drug from ImmunoGen takeover

AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically cleared for folate receptor-alpha (FRα) positive, platinum-resistant

News

BMS hands back rights to cancer ADC licensed from Eisai

Bristol-Myers Squibb has ended a $3.1 billion strategic collaboration with Eisai focusing on antibody-drug conjugates (ADCs) and returned rights to the lead drug in the alliance.

ESMO26: Lilly's sofe-m ADC stakes a claim in ovarian cancer

AbbVie's ovarian cancer drug Elahere gets NHS green light

Data backs GSK's ovarian cancer blockbuster hopes

AbbVie builds the case for ovarian cancer drug Elahere

AbbVie bags EU nod for key drug from ImmunoGen takeover

BMS hands back rights to cancer ADC licensed from Eisai

Flagship joins three biotechs together to form Etcelera

Discover a new era of healthcare panel engagement: Grounded ...

Elahere

Editor's Picks